See this page online at: http://www.biotechfocus.com/2008Issue2
 |
Sign up for your subscription and keep up-to-date.
Stay updated on the latest news and technologies with Bioscienceworld's newsletters.
Five to choose from.
|
Enhancing Canada's Preparedness to Deal Wtih Emerging Infectious Diseases
By Shawn Lawrence
The skin infection known as the ‘Staph’ has been around for as long as medicine has been practiced. With the introduction of antibiotics in the 1940’s and 50’s, the ‘Staph’ was treatable and quite sensitive to penicillin. That all changed just a few decades later when a new strain of ‘Staph’ emerged, dubbed methicillin-resistant Staphylococcus aureus (MRSA). |
|
Biotechnology in Canada: Opportunities and Challenges
By Michael Herman, Robert Ford, Paul Fortin and Alain Morin
The biotechnology industry in Canada had an eventful year in 2007. |
|
Migenix Takes Products From Conceptualization to Commercialization
By Deanna Natalizio
From conceptualization to commercialization, the process of drug development is pushed along by many helping hands. Migenix, a company specializing in the product development of infectious and degenerative diseases, has a philosophy of taking a collaborative approach to drug development. |
|
How Shrinking VC Investment is Hurting the Canadian Medical Device Sector
By Shawn Lawrence
Employing nearly 35,000 people in approximately 1,500 corporate facilities across the country and drawing on the work conducted in universities, research institutes and hospitals, the Canadian medical-device industry appears on the surface, very healthy. Relative to many countries and in terms of innovation the sector is a very real powerhouse. But scratch below the surface and there could be troubling times ahead. |
